Nipocalimab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Nipocalimab Usage And Synthesis

Uses

Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases[1][2][3].

in vivo

References

[1] James S Castleman, et al. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. Br J Haematol. 2021 Feb;192(3):425-432. DOI:10.1111/bjh.17041
[2] Ling L E, et al. Selective targeting of FcRn and IgG clearance by nipocalimab preserves key immune functions. Hematology, Transfusion and Cell Therapy, 2022, 44: S13.
[3] Marinos C Dalakas, et al. The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021 Feb 26;14:1756286421997381. DOI:10.1177/1756286421997381

Nipocalimab(2211985-36-1)Related Product Information

• Panitumumab
• Trastuzumab
• Abciximab
• Nimotuzumab
• Matuzumab
• Pertuzumab
• Batoclimab
• Rozanolixizumab
• OMALIZUMAB
• Aprutumab